112 CHAPTER 4 92 Faronato, M. et al. Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol Histopathol 22, 1109-1118 (2007). 93 Matsuyama, M. et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 14, 73-79 (2005). 94 Gudas, L. J., Fu, L. P., Minton, D. R., Mongan, N. P. & Nanus, D. M. The role of HIF1 alpha in renal cell carcinoma tumorigenesis. J Mol Med 92, 825-836, doi:10.1007/s00109-014-1180-z (2014). 95 Xu, J. S. et al. High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome. Oncology Letters 8, 687-692, doi:10.3892/ol.2014.2196 (2014). 96 Feng, Z. H. et al. RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25. Cancer Sci 108, 1620-1627, doi:10.1111/cas.13297 (2017). 97 Lee, S. J. et al. Von Hippel-Lindau Tumor Suppressor Gene Loss in Renal Cell Carcinoma Promotes Oncogenic Epidermal Growth Factor Receptor Signaling via Akt-1 and MEK-1. Eur Urol 54, 845-854, doi:10.1016/j.eururo.2008.01.010 (2008). 98 Minner, S. et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer-Am Cancer Soc 118, 1268-1275, doi:10.1002/cncr.26436 (2012). 99 Liu, C. et al. VHL-HIF-2 alpha axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR. Oncogene 39, 4286-4298, doi:10.1038/s41388-020-1291-7 (2020). 100 Xu, C. & Zheng, J. H. siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma - involvement of c-myc, cyclin E1, and CDK2. Cell Mol Biol Lett 24, doi:ARTN 7 10.1186/ s11658-018-0124-y (2019). 101 Sun, G. G., Wei, C. D., Jing, S. W. & Hu, W. N. Interactions between Filamin A and MMP-9 Regulate Proliferation and Invasion in Renal Cell Carcinoma. Asian Pac J Cancer P 15, 3789-3795, doi:10.7314/ Apjcp.2014.15.8.3789 (2014). 102 De Palma, G. et al. The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma. Journal of Cancer 7, 1960-1967, doi:10.7150/jca.16123 (2016). 103 Tsai, T. H. & Lee, W. Y. Succinate Dehydrogenase-Deficient Renal Cell Carcinoma. Archives of Pathology & Laboratory Medicine 143, 643-647, doi:10.5858/arpa.2018-0024-RS (2019). 104 Billemont, B. et al. Angiogenesis and renal cell carcinoma. B Cancer 94, S232-S240 (2007). 105 Horstmann, M. et al. Evaluation of the KIT/Stem Cell Factor Axis in Renal Tumours. Anticancer Res 32, 4339-4345 (2012). 106 Shen, C. & Kaelin, W. G. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 23, 18-25, doi:10.1016/j.semcancer.2012.06.001 (2013). 107 Looyenga, B. D. et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. P Natl Acad Sci USA 108, 1439-1444, doi:10.1073/pnas.1012500108 (2011).
RkJQdWJsaXNoZXIy MTk4NDMw